Compare NEOS S&P 500 High Income ETF (SPYI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NEOS S&P 500 High Income ETF vs TransMedics Group Inc — how do they compare? NEOS S&P 500 High Income ETF trades at $54.09 (market cap $12.50B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: NEOS S&P 500 High Income ETF is far larger — about 4.6× TransMedics Group Inc's market cap, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NEOS S&P 500 High Income ETF for 58 Days and TransMedics Group Inc for 24 Days on average.
| SPYI | TMDX | |
|---|---|---|
Market Cap | $12.50B | $2.74B |
Volume | 3,058,962 | 949,331 |
Sector | Income / Options Overlay | Health |
52-Week High | $54.42 | $150.42 |
52-Week Low | $47.98 | $61.99 |
Typical Hold Time | 58 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPYI trades at $54.095 with a modest 0.16% daily gain, showing bullish technical momentum with strong moving average signals. The ETF maintains consistent monthly dividend distributions around $0.53-0.54 per share, targeting income-focused investors. Recent news highlights SPYI's popularity among retirement portfolios while raising concerns about principal erosion from covered call strategies.
The outlook remains mixed - strong technicals and high yield appeal support near-term stability, but long-term capital preservation risks from the covered call strategy warrant caution. Income investors benefit from consistent distributions, though growth-oriented investors may find the strategy limiting during bull markets.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
